How does semaglutide work for weight loss?

Semaglutide mimics GLP-1, a hormone that regulates appetite and blood sugar. It slows gastric emptying, promotes insulin release when glucose is elevated, and crosses the blood-brain barrier to reduce hunger signalling in the hypothalamus. In clinical trials, it produced 10-17% body weight reduction depending on dose and formulation.

What is the difference between oral and injectable semaglutide?

Injectable semaglutide (Ozempic/Wegovy) has ~89% bioavailability and is dosed once weekly. Oral semaglutide (Rybelsus) uses SNAC technology to survive stomach acid but has only ~1% bioavailability, requiring a 14 mg daily tablet to match the systemic exposure of a 1 mg weekly injection. Injectable versions generally achieve higher peak weight loss.

Is semaglutide safe for long-term use?

The SELECT trial followed over 17,000 patients for 4 years and showed a 20% reduction in cardiovascular events with an acceptable safety profile. Common side effects are gastrointestinal (nausea, diarrhea). The main long-term concerns are lean mass loss, gallbladder events, and weight regain after discontinuation. Semaglutide carries an FDA boxed warning for thyroid C-cell tumours based on rodent data, though this has not been observed in humans.

Does semaglutide cause muscle loss?

Yes. DXA data from the STEP 1 trial showed that approximately 40% of total weight lost was lean mass (muscle, bone, water). This risk can be mitigated with adequate protein intake (1.2-1.5 g/kg daily) and structured resistance training to preserve muscle tissue during treatment.

What happens when you stop taking semaglutide?

Extension data from the STEP trials showed that approximately two-thirds of lost weight returns within one year of discontinuation, along with reversal of cardiometabolic benefits. This suggests semaglutide may function as a maintenance therapy rather than a cure, though lifestyle factors (diet, exercise) influence individual outcomes.

Can semaglutide help with heart disease?

Yes. The SELECT trial (N=17,604) demonstrated a 20% reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in overweight/obese adults. The SOUL trial showed a 14% MACE reduction with the oral formulation. These are among the strongest cardiovascular outcome signals in the GLP-1 class.

Does semaglutide help with fatty liver disease (MASH)?

The ESSENCE Phase 3 trial showed 62.9% of patients achieved MASH resolution without worsening fibrosis, and 37% had fibrosis improvement by at least one stage. The FDA granted accelerated approval for MASH with moderate to advanced fibrosis in August 2025.

What is the correct semaglutide dosing schedule?

For subcutaneous injection: start at 0.25 mg weekly for 4 weeks, escalate to 0.5 mg for 4 weeks, then 1.0 mg (for T2D) or continue titrating to 1.7 mg and 2.4 mg (for weight management). For oral: start at 3 mg daily for 30 days, then 7 mg daily for 30 days, then 14 mg daily. Slow titration reduces gastrointestinal side effects.

Semaglutide: GLP-1 Peptide Profile

Semaglutide is a synthetic GLP-1 receptor agonist with 94% sequence homology to native human GLP-1. Three structural modifications extend its half-life to approximately 160 hours (~1 week):

Aib8 substitution: Replaces alanine at position 8, blocking DPP-4 enzymatic cleavage that normally degrades native GLP-1 within 2 minutes.
Arg34 substitution: Stabilises the peptide backbone against further proteolytic attack.
Lys26 C18 fatty diacid acylation: Attaches a fatty acid spacer that binds reversibly to serum albumin, creating a circulating reservoir that releases active peptide gradually.

Once bound to the GLP-1 receptor, semaglutide triggers four parallel cascades:

Glucose-dependent insulin secretion: Stimulates pancreatic beta-cells only when blood glucose is elevated, avoiding hypoglycaemia in isolation.
Glucagon suppression: Reduces hepatic glucose output by inhibiting alpha-cell glucagon release.
Delayed gastric emptying: Slows nutrient transit, reducing postprandial glucose spikes and contributing to satiety.
Central appetite regulation: Crosses the blood-brain barrier to activate hypothalamic GLP-1 receptors, reducing hunger signalling and modulating the mesolimbic reward system.

The central nervous system effects are particularly significant: semaglutide dampens dopamine surges in the ventral tegmental area (VTA) and increases GABAergic tone in the central amygdala, which may explain emerging signals in addiction treatment beyond appetite suppression.

Weight Reduction

Semaglutide consistently delivers clinically meaningful weight loss across multiple Phase 3 programs:

SELECT trial (N=17,604): 10.2% mean body weight reduction sustained over 4 years in overweight/obese adults with established cardiovascular disease.
STEP trials (N=1,961): 15-17% mean body weight reduction over 68 weeks at 2.4 mg weekly dose.
Oral formulation: 10-12% weight loss with 14 mg daily Rybelsus, reflecting lower systemic exposure due to ~1% oral bioavailability.

Composition of Weight Loss

DXA scans from STEP 1 reveal that lean mass (muscle, bone, water) accounts for approximately 40% of total weight lost. This creates a real risk of sarcopenic obesity, where a patient reaches a "healthy" BMI but lacks functional muscle for metabolic health. Mitigation requires:

Protein intake: 1.2-1.5 g/kg body weight daily to act as a metabolic brake on muscle proteolysis.
Resistance training: Structured programme providing the mechanical stimulus for myofibrillar preservation.

Glycaemic Control

The SUSTAIN programme (N>8,000) demonstrated dose-dependent HbA1c reductions of 1.5-1.8% in type 2 diabetes, with a significant proportion of patients achieving target HbA1c of 6.5% or below.

Cardiovascular Outcomes

Semaglutide has crossed the threshold from metabolic drug to cardiovascular protector:

SELECT trial: 20% relative risk reduction in Major Adverse Cardiovascular Events (MACE: cardiovascular death, non-fatal MI, non-fatal stroke) in overweight/obese adults without diabetes. N=17,604 over 4 years.
SOUL trial (oral, N=9,650): 14% MACE reduction with oral semaglutide, extending cardiovascular protection to the tablet formulation.
STEP-HFpEF (N=529): Heart failure with preserved ejection fraction patients saw a 16.6-point improvement in Kansas City Cardiomyopathy Questionnaire scores, nearly double the placebo response.
Blood pressure: -3.4 mmHg systolic reduction as SELECT secondary endpoint.

Kidney Protection

The FLOW trial (N=3,533) demonstrated that semaglutide reduced the composite kidney endpoint (sustained eGFR decline, kidney failure, cardiovascular death, renal death) by 24% in patients with type 2 diabetes and chronic kidney disease. This establishes GLP-1 agonism as a renal-protective pathway independent of glucose control.

Anti-inflammatory Signal

SELECT secondary analysis showed a 37% reduction in high-sensitivity C-reactive protein (hs-CRP), suggesting systemic anti-inflammatory effects that may partially explain the cardiovascular and renal benefits beyond weight loss and glucose control alone.

Metabolic dysfunction-associated steatohepatitis (MASH) represents one of semaglutide's most significant therapeutic expansions. The FDA granted accelerated approval on August 15, 2025, for adults with MASH and moderate to advanced fibrosis.

ESSENCE Phase 3 Results

MASH resolution: 62.9% of semaglutide-treated patients achieved steatohepatitis resolution without worsening fibrosis, compared to 34.3% with placebo.
Fibrosis improvement: 37% achieved fibrosis improvement by at least one stage, compared to 22.5% with placebo. This contradicted earlier Phase 2b data that showed no fibrosis signal, representing a meaningful shift in the evidence base.

Outstanding Questions

Current MASH data relies on surrogate histological markers (liver biopsies). Hard outcomes, including progression to cirrhosis, need for liver transplant, and overall mortality, remain unresolved and require longer follow-up. These are the endpoints that will determine whether semaglutide truly changes the natural history of MASH or simply improves biopsy snapshots.

Alcohol Use Disorder

Semaglutide's modulation of the mesolimbic reward system has produced striking signals in alcohol use disorder (AUD):

Danish RCT: 41.1 percentage-point reduction in heavy-drinking days.
Swedish registry (N>220,000): 50-56% risk reduction for alcohol-related hospitalisation.
Mechanism: Dampened dopamine surges in the VTA and increased GABAergic tone in the central amygdala reduce the "wanting" component of reward-seeking behaviour.

An important caveat: earlier exenatide data showed a BMI-dependent split where lean participants (BMI <25) actually saw increased heavy drinking. Current semaglutide data suggests a broader therapeutic window, but safety in lean individuals remains uncertain.

Obstructive Sleep Apnoea

STEP-OSA trials demonstrated AHI (apnoea-hypopnoea index) reduction, with observational data suggesting up to 50% reduction in incident sleep apnoea. Semaglutide does not yet have a specific FDA approval for this indication.

Other Signals

PCOS: Multiple pilot studies show improved metabolic and androgenic parameters in polycystic ovary syndrome.
Neuroprotection: Small fMRI studies and preclinical models suggest enhanced brain insulin sensitivity and reduced neuroinflammation, though human outcome trials are absent.
Non-alcohol addictions: Data for cannabis, nicotine, cocaine, and opioid use disorders remain observational or early preclinical.

Semaglutide is available in two formulations with fundamentally different pharmacokinetic profiles:

Subcutaneous (Ozempic/Wegovy): ~89% bioavailability. 1 mg delivers approximately 1 mg systemically. Dosed once weekly.
Oral (Rybelsus): ~1% bioavailability. Uses SNAC (sodium N-(8-[2-hydroxybenzoyl] amino) caprylate) absorption technology to create localised pH elevation in the stomach, shielding the peptide from acid degradation. A 14 mg daily tablet achieves roughly the same systemic exposure as 1 mg weekly injection.

Practical Requirements for Oral Dosing

The oral formulation demands a strict morning routine: take on an empty stomach with no more than 120 mL (4 oz) of plain water, then wait at least 30 minutes before eating, drinking, or taking other medications. Deviation from this protocol significantly reduces absorption.

Compounding Warning

Grey-market or compounded oral versions that lack SNAC absorption technology will have near-zero bioavailability and are effectively inactive. This is one of the most critical sourcing distinctions for semaglutide specifically: an injectable compounded version may retain potency, but an oral compounded version without SNAC is pharmacologically useless.

Semaglutide has evolved from a diabetes drug into a multi-systemic metabolic agent with cardiovascular, renal, hepatic, and neurological implications. The clinical evidence base is unusually large for a peptide: SELECT alone enrolled over 17,000 participants. Open questions remain around lean mass preservation, post-discontinuation weight regain, long-term MASH outcomes, and the boundaries of its addiction-related effects. Whether semaglutide becomes a lifelong maintenance therapy or a bridge to sustainable lifestyle change will depend on how clinicians integrate it with protein, resistance training, and metabolic monitoring.

1.Mechanism of Action

Explore This Protocol

Safety Triggers

Research Gaps

Contrarian Views

Protocol Reference

Related Research

Tirzepatide

Blood Sugar Regulation

Appetite Suppression

Neuroprotection

Insulin Sensitivity

Cardiovascular Health

Stay Ahead of the Research

2.Weight Loss and Metabolic Outcomes